InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

Rhea-AI Summary

InterCure (Nasdaq: INCR) received a Nasdaq notice on February 25, 2026 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5450(a)(2).

The company has a 180-calendar day compliance period until August 24, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. InterCure may seek an additional 180-day period by submitting a transfer application and intends to consider a reverse share split as part of its compliance plan.

Positive

• Shares continue trading on the Nasdaq Global Market during compliance period
• 180-day compliance window granted until August 24, 2026 to regain minimum bid
• Potential extension via an additional 180-day period if transfer application conditions are met

Negative

• Closing bid below $1.00 for 30 consecutive business days as of February 25, 2026
• Delisting risk if the company does not regain compliance within the compliance periods
• Management may pursue a reverse share split to restore compliance, which requires approvals

News Market Reaction – INCR

+2.40%

1 alert

+2.40% News Effect

+$1M Valuation Impact

$48M Market Cap

0.1x Rel. Volume

On the day this news was published, INCR gained 2.40%, reflecting a moderate positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $48M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Minimum bid price: $1.00 per share Non-compliance period: 30 consecutive business days Initial compliance period: 180 calendar days +5 more

8 metrics

Minimum bid price $1.00 per share Nasdaq Listing Rule 5450(a)(2) requirement

Non-compliance period 30 consecutive business days Closing bid below $1.00 per share

Initial compliance period 180 calendar days Period to regain minimum bid compliance to August 24, 2026

Compliance deadline August 24, 2026 End of initial 180-day bid price compliance window

Required compliant days 10 consecutive business days Bid must meet or exceed $1.00 per share

Potential extension period Additional 180 calendar days Possible extra time on Nasdaq Capital Market if conditions met

Listing Rule 5450(a)(2) Rule 5450(a)(2) Nasdaq minimum bid price requirement cited in notice

Listing Rule 5810(c)(3)(A) Rule 5810(c)(3)(A) Defines 180-day compliance period for bid deficiency

Market Reality Check

Price: $0.8202 Vol: Volume 7,597 is well belo...

low vol

$0.8202 Last Close

Volume Volume 7,597 is well below the 20-day average of 63,773 (relative volume 0.12x). low

Technical Shares trade below the 200-day MA of 1.37 with a current price of 0.8301, far under the 52-week high of 1.7698.

Peers on Argus

INCR was up 2.36% while only one scanned peer (SXTC) appeared in momentum data, ...

1 Down

INCR was up 2.36% while only one scanned peer (SXTC) appeared in momentum data, moving down. Other close peers showed mixed, modest moves, indicating a stock-specific reaction to the Nasdaq bid-price notice rather than a broad sector move.

Historical Context

4 past events · Latest: Feb 19 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Preliminary 2025 results	Positive	-5.8%	Estimated 2025 revenue and cash position with continued positive Adjusted EBITDA.
Nov 03	Strategic collaboration	Positive	+4.3%	Cannasoul investment and collaboration to advance cannabis science and innovation.
Oct 08	H1 2025 earnings	Positive	-0.3%	Reported higher revenue, positive EBITDA and operating cash flow, modest net loss.
Sep 19	ISHI acquisition	Positive	-2.0%	All-share deal for ISHI to add premium cannabis tech and U.S. partnerships.

Pattern Detected

Recent fundamentally positive updates have sometimes been followed by flat or negative next-day price reactions.

Recent Company History

Over the last six months, InterCure has emphasized growth and strategic expansion. On Oct 8, 2025, it reported NIS 130 million first-half revenue and positive operating cash flow. On Sep 19, 2025, it announced the ISHI acquisition for shares equal to about 10% of fully diluted equity. Subsequent filings highlighted collaboration with Cannasoul and preliminary 2025 revenue of NIS 265 million and positive Adjusted EBITDA. Today’s Nasdaq minimum bid notification contrasts these operational gains with sustained share-price weakness.

Market Pulse Summary

This announcement details Nasdaq’s minimum bid price deficiency process after 30 consecutive days be...

Analysis

This announcement details Nasdaq’s minimum bid price deficiency process after 30 consecutive days below $1.00. InterCure has an initial 180-day window, potentially extendable by another 180 days, to achieve at least 10 consecutive days with a bid at or above $1.00. The company mentions a possible reverse share split as a tool. Investors may track compliance milestones, corporate approvals, and any follow-up filings explaining how management plans to maintain Nasdaq listing standards.

Key Terms

nasdaq global market, nasdaq capital market, reverse share split, minimum bid price requirement, +2 more

6 terms

nasdaq global market regulatory

"The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

nasdaq capital market regulatory

"listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

reverse share split financial

"to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

minimum bid price requirement regulatory

"plan to regain compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

delisting regulatory

"Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting"

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

deficiency notification regulatory

"This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification"

A deficiency notification is a formal notice from a regulator, exchange, or reviewer pointing out missing, unclear, or inadequate information in a company’s filing or application. It matters to investors because it can delay approvals, listings, fundraising or product launches and signal compliance or disclosure problems; think of it as a teacher returning a homework sheet with items circled that must be fixed before the work is accepted.

AI-generated analysis. Not financial advice.

NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.

If the Company is not in compliance by August 24, 2026, the Company expects to be eligible for an additional 180-calendar day compliance period. To qualify for this additional time, the Company will be required to submit a transfer application and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and to provide written notice of its intention to cure the deficiency during such period.

The Company currently intends monitor the closing price of its Ordinary Shares and to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals, as part of its plan to regain compliance with the minimum bid price requirement, and believes that this measure, together with its ongoing business and strategic initiatives, will support the restoration of compliance within the applicable timeframe. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Forward-Looking Statements

This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, obtain required approvals for any corporate actions, including a reverse share split, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co 

FAQ

Why did InterCure (INCR) receive a Nasdaq minimum bid notice on February 25, 2026?

Because the closing bid price fell below $1.00 for 30 consecutive business days. According to the company, Nasdaq notified it under Listing Rule 5450(a)(2) and granted a compliance period to cure the deficiency.

What is the deadline for InterCure (INCR) to regain Nasdaq compliance?

The initial deadline is August 24, 2026, a 180-calendar day period from the notice. According to the company, the stock must close at $1.00 or higher for 10 consecutive business days to regain compliance.

Can InterCure (INCR) get more time from Nasdaq to regain the $1.00 minimum bid?

Yes. The company may be eligible for an additional 180-calendar day period by submitting a transfer application. According to the company, this requires meeting Nasdaq listing standards except the minimum bid rule and providing written intent to cure.

Will InterCure (INCR) be delisted immediately after the Nasdaq notice?

No. Trading on the Nasdaq Global Market continues during the compliance period. According to the company, delisting would occur only if compliance is not achieved within the allotted period(s) and Nasdaq issues a delisting notice.

What steps is InterCure (INCR) considering to regain Nasdaq compliance?

The company intends to monitor its share price and consider a reverse share split as part of its plan. According to the company, any reverse split would require necessary corporate and regulatory approvals.